Waregem (Belgium) / Rotterdam (the Netherlands)[1], 8 May 2013 – Arseus discloses the information with respect to the acquisition of treasury shares required under Article 207 of the Royal Decree of 30 January 2001 implementing the Belgian Company Code.
Arseus today announces that during the period from 30 April 2013 to 8 May 2013, it acquired 40,444 treasury shares on NYSE Euronext Brussels (through an intermediate, acting with a discretionary mandate).
shares Average
price Lowest
price Highest
price Amount 30 April 2013 8,444 € 19.9502 € 19.73 € 20.08 € 168,459 2 May 2013 6,335 € 19.8043 € 19.76 € 20.00 € 125,460 3 May 2013 5,934 € 19.7869 € 19.72 € 20.00 € 117,415 6 May 2013 7,922 € 20.1129 € 19.95 € 20.22 € 159,334 7 May 2013 1,238 € 20.1706 € 20.00 € 20.20 € 24,971 8 May 2013 10,571 € 20.6167 € 20.20 € 20.80 € 217,939
In addition, during the period from 30 April 2013 to 8 May 2013, Arseus acquired 24,000 treasury shares via various block trades.
The Extraordinary Shareholders’ Meeting held on 16 June 2009 renewed the authorisation of the Board of Directors to acquire treasury shares.
Prior to the transactions, Arseus held 924,546 treasury shares. As a result of the acquisition of 64,444 treasury shares, the exercise of stock options by members of the Board of Directors, members of the Executive Committee and employees of Arseus, and the transfer 14,298 shares as subsequent payment for an acquisition, Arseus now holds 59,646 treasury shares, representing 0.19% of the total number of shares outstanding.
In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.
For more information:
Constantijn van Rietschoten
Director of Corporate Communications
+31 88 33 11 222 (Office)
+31 6 53 69 15 85 (Mobile)
constantijn.van.rietschoten@arseus.com
Arseus profile
Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in 30 countries worldwide. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICT-solutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.
[1] This press release was sent out by Arseus NV and Arseus BV.
Please open the link below for the press release: